A washout for Pfizer/J&J Alzheimer's drug in first PhIII study

The first Phase III data on a proposed Alzheimer's drug dashed hopes at Pfizer ($PFE) and Johnson & Johnson ($JNJ). Bapineuzumab failed to best placebo at easing symptoms of mild-to-moderate disease. Report